Special Populations
20
Table 4. Vaccinations Prior to or After Allogeneic or
Autologous HSCT
R, recommended—administer if not previously administered or not current; such patients may be at
increased risk for this vaccine-preventable infection
posttx, posttransplant; U, usual—administer if patient not current with recommendations for dose(s)
of vaccine for immunocompetent persons in risk and age categories
X, contraindicated.
a
ese live vaccines should not be administered unless the vaccine is otherwise indicated based on the
annually updated CDC recommendations AND the patient is not immunosuppressed AND there
will be an interval of ≥4 weeks prior to transplant.
b
Administer to adolescents and adults (SR-L) and to children (SR-M) if measles-seronegative,
the timing is ≥24 months aer transplant, no GVHD is present, and the patient is not receiving
immunosuppressive medication. Two doses should be administered.
c
If not previously administered.
d
Administer if varicella-seronegative, the timing is ≥24 months aer transplant, no GVHD is present,
and the patient is not receiving immunosuppressive medication. Two doses should be administered
(SR-L).
e
Consider if the patient is not severely immunosuppressed and the patient is varicella-immune as
defined by documentation of age-appropriate varicella vaccination, serologic evidence of immunity,
documentation of varicella or zoster infection, or birth in the United States before 1980 and there
will be an interval of ≥4 weeks prior to transplant.
* is recommendation deviates from CDC ACIP recommendations.
